Granted Patent B2

US 11,161,913 · App. 17/220,387 · Granted Nov 2, 2021

Inventors: Lei Xiao (Rockville, MD); He Sun (Shanghai, CN); Zhiyuan Cao (Shanghai, CN); Wensheng Wang (Shanghai, CN); Chengfei Pu (Shanghai, CN); Li Mao (Shanghai, CN)

Assignees: Innovative Cellular Therapeutics Holdings, Ltd.; Innovative Cellular Therapeutics, Inc.

C07K16/40A61K47/6801C07K2317/622

Abstract

Claims (13)

1. An antibody that binds ACPP, wherein the antibody comprises a heavy chain variable region (HVR) comprising amino acid sequence SEQ ID NO: 83 and a light chain variable region (LVR) comprising amino acid sequence SEQ ID NO: 82.

2. The antibody of claim 1 , wherein the HVR is joined to a human IgG chain constant region.

3. The antibody of claim 2 , wherein the human IgG comprises IgG1 or IgG3.

4. The antibody of claim 1 , wherein the antibody is conjugated to a cytotoxic agent.

5. The antibody of claim 4 , wherein the cytotoxic agent comprises a radioactive isotope or a toxin.

6. The antibody of claim 1 , wherein SEQ ID NO: 83 and SEQ ID NO: 82 are joined by a linker.

7. The antibody of claim 6 , wherein the linker comprises SEQ ID NO: 24 or SEQ ID NO: 184.

8. The antibody of claim 1 , wherein the antibody comprises a scFv.

9. The antibody of claim 8 , wherein the scFv comprises a linker joining SEQ ID NO: 82 and SEQ ID NO: 83.

10. The antibody of claim 8 , wherein the scFv comprises amino acid sequence SEQ ID NO: 173.

11. The antibody of claim 8 , wherein the antibody is conjugated to a cytotoxic agent.

12. The antibody of claim 11 , wherein the cytotoxic agent comprises a radioactive isotope or a toxin.

13. The antibody of claim 9 , wherein the linker comprises SEQ ID NO: 24 or SEQ ID NO: 184.

Assignments (2)

Continuity (8)